Spero Therapeutics, Inc. Payments to Acquire Marketable Securities
Spero Therapeutics, Inc. (SPRO) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2024-03-13
- Spero Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-12-31 was $0.00.
- Spero Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-09-30 was $0.00.
- Spero Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-06-30 was $0.00.
- Spero Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Spero Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $26.97M, a 38.59% decline from fiscal 2021.
- Spero Therapeutics, Inc. payments to acquire marketable securities for fiscal 2021 was $43.91M, a 3.95% decline from fiscal 2020.
- Spero Therapeutics, Inc. payments to acquire marketable securities for fiscal 2020 was $45.72M, a 48.62% decline from fiscal 2019.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $26.97M 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $26.97M 10-Q · filed 2023-11-13 | $57.28M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $26.97M 10-Q · filed 2023-08-10 | $57.28M derived: sum of 3 quarters · filed 2023-08-10 | $58.31M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $26.97M 10-Q · filed 2023-05-11 | $57.28M derived: sum of 2 quarters · filed 2023-05-11 | $58.31M derived: sum of 3 quarters · filed 2023-05-11 | $67.89M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $30.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $31.34M derived: sum of 2 quarters · filed 2023-03-30 | $40.92M derived: sum of 3 quarters · filed 2023-03-30 | $43.91M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $10.60M derived: sum of 2 quarters · filed 2022-11-14 | $13.60M 10-Q · filed 2022-11-14 | $55.33M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $9.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $12.58M 10-Q · filed 2022-08-10 | $54.31M derived: sum of 3 quarters · filed 2022-08-10 | $54.31M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $3.00M 10-Q · filed 2022-05-16 | $44.73M derived: sum of 2 quarters · filed 2022-05-16 | $44.73M derived: sum of 3 quarters · filed 2022-05-16 | $44.73M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $41.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $41.73M derived: sum of 2 quarters · filed 2022-03-31 | $41.73M derived: sum of 3 quarters · filed 2022-03-31 | $45.72M 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $4.00M 10-Q · filed 2021-11-10 | $16.46M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $4.00M 10-Q · filed 2021-08-05 | $16.46M derived: sum of 3 quarters · filed 2021-08-05 | $60.13M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $4.00M 10-Q · filed 2021-05-06 | $16.46M derived: sum of 2 quarters · filed 2021-05-06 | $60.13M derived: sum of 3 quarters · filed 2021-05-06 | $67.15M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $12.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $56.14M derived: sum of 2 quarters · filed 2021-03-11 | $63.16M derived: sum of 3 quarters · filed 2021-03-11 | $88.99M 10-K · filed 2021-03-11 |
| 2019-09-30 | $43.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $50.69M derived: sum of 2 quarters · filed 2020-11-05 | $76.52M 10-Q · filed 2020-11-05 | $102.28M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $7.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $32.85M 10-Q · filed 2020-08-06 | $58.61M derived: sum of 3 quarters · filed 2020-08-06 | $140.20M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $25.84M 10-Q · filed 2020-05-08 | $51.59M derived: sum of 2 quarters · filed 2020-05-08 | $133.19M derived: sum of 3 quarters · filed 2020-05-08 | $133.19M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $25.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $107.35M derived: sum of 2 quarters · filed 2020-03-16 | $107.35M derived: sum of 3 quarters · filed 2020-03-16 | $130.18M 10-K · filed 2020-03-16 |
| 2018-09-30 | $81.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $81.60M derived: sum of 2 quarters · filed 2019-11-04 | $104.42M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $22.82M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $22.82M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |